Quest Diagnostics Maintains 'Safe Haven' Status with Strong Q1 Performance Quest Diagnostics posted first quarter revenues of $2.65 billion, up 12% year-over-year, and adjusted earnings of $2.21 per share, beating analyst estimates. The company reaffirmed its full-year guidance, with analysts noting Quest’s resilience and stability amid broader market volatility, reinforcing its reputation as a defensive healthcare stock.56